Haemonetics Co. (NYSE:HAE) Shares Bought by Aristotle Capital Boston LLC

Aristotle Capital Boston LLC lifted its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 6.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 380,617 shares of the medical instruments supplier's stock after purchasing an additional 22,011 shares during the period. Aristotle Capital Boston LLC owned approximately 0.76% of Haemonetics worth $29,719,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its stake in shares of Haemonetics by 1.2% in the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock valued at $1,160,000 after buying an additional 181 shares during the period. Parkside Financial Bank & Trust lifted its holdings in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the last quarter. HighTower Advisors LLC boosted its position in shares of Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 244 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the 4th quarter worth about $25,000. Finally, Xponance Inc. increased its stake in Haemonetics by 5.9% in the fourth quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock valued at $566,000 after purchasing an additional 404 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Performance

Shares of NYSE:HAE traded up $0.62 during midday trading on Wednesday, hitting $64.20. The stock had a trading volume of 986,131 shares, compared to its average volume of 693,281. The company has a market capitalization of $3.23 billion, a PE ratio of 25.28, a P/E/G ratio of 1.11 and a beta of 0.32. Haemonetics Co. has a 1 year low of $55.30 and a 1 year high of $97.97. The stock has a 50 day moving average price of $62.67 and a two-hundred day moving average price of $71.54. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Raymond James reaffirmed a "strong-buy" rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. StockNews.com raised Haemonetics from a "hold" rating to a "buy" rating in a report on Monday. Barrington Research dropped their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. Finally, Needham & Company LLC cut their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.